So, after last week’s pretty good, this week we shouldn’t expect much, right? This week instead has turned out to be … variable. The stock indices tell this story: The NASDAQ composite eked out a modest gain, +0.7%, after all the excitement in the early part of the week. But the S&P Biotech Index took a hit of -0.3%. On the other hand the NASDAQ Biotech Index outperformed its broader brethren, up +1.2%.
Looking at the individual issues, the top end showed real gains: IMVT up +63% of the week, (because of a new public offering, equal to 10% of the current equity); PRVB up +54% because of signing a marketing/developing agreement with another company for its lead investigational drug candidate (i.e. currently unapproved); and AUTL is up +45% because it is licensing a chunk of its IP to Bristol-Myers-Squibb. At least there are reasons for the moves out in the open. The big loser, KALV (-66%), had announced the termination of a Phase II “reevaluation” study on Tuesday. In terms of YTD performance, last week’s top five just shuffled a bit between themselves, ditto for the bottom 5.
The contest portfolios were generally significantly better than the indices, up +4.4% on average (+3.5% for the median). Only ten portfolios were in the red for the week. Interestingly only one of the top 10 YTD portfolios were among the big winners for the week, BULBAMAN, up 15.3%, to rejoin the list after a three week absence. The gap between the first and second place YTD portfolios, DIEGOSAN and DEW DILIGENCE, has been narrowing over the last few weeks from 9.2% to this weeks 5.2%. Still a horse race.
|
Report Time Ranges
|
|
|
From
|
To
|
Recent
|
9/30/22
|
10/7/22
|
YTD
|
12/31/21
|
Index Performance
|
|
Symbol
|
Recent
|
YTD
|
|
^IXIC
|
0.73%
|
-31.91%
|
^NBI
|
1.17%
|
-19.39%
|
^SPSIBI
|
-0.31%
|
-29.27%
|
Share Performance
|
Recent
|
YTD
|
Top 5
|
Bottom 5
|
Top 5
|
Bottom 5
|
IMVT
|
62.903%
|
KALV
|
-65.886%
|
CBIO
|
122.73%
|
GNCA
|
-99.38%
|
PRVB
|
53.778%
|
BBLG
|
-44.743%
|
OPTN
|
113.58%
|
PTE
|
-95.06%
|
AUTL
|
44.860%
|
VSTM
|
-42.941%
|
BIOA-B.ST
|
81.43%
|
VLON
|
-94.93%
|
EYEN
|
40.153%
|
GNCA
|
-38.983%
|
RVNC
|
79.96%
|
PLXP
|
-92.63%
|
MYOV
|
38.697%
|
SNWV
|
-29.217%
|
FENC
|
76.82%
|
ATHX
|
-92.58%
|
|
Top 10 Portfolio YTD
|
YTD(Portfolio - SPSIBI)
|
Rec
|
Rec(Port. - SPSIBI)
|
DIEGOSAN
|
-4.05%
|
25.22%
|
-0.185%
|
0.121%
|
DEW DILIGENCE
|
-9.21%
|
20.06%
|
1.915%
|
2.221%
|
TECHNETIUM
|
-12.84%
|
16.43%
|
2.706%
|
3.012%
|
BIOSCIENTISTSA
|
-20.18%
|
9.09%
|
5.213%
|
5.519%
|
HORSEINALFALFA
|
-23.25%
|
6.02%
|
5.297%
|
5.603%
|
ROCKY9
|
-23.91%
|
5.36%
|
4.738%
|
5.044%
|
GENEGURU
|
-24.60%
|
4.67%
|
3.276%
|
3.581%
|
BRENDAN_49
|
-25.23%
|
4.04%
|
2.143%
|
2.448%
|
BULBAMAN
|
-26.80%
|
2.47%
|
15.307%
|
15.612%
|
A.J. MULLEN
|
-27.29%
|
1.98%
|
2.420%
|
2.726%
|
Average and Median Portfolio Performance
|
|
Avg Recent
|
Avg YTD
|
Median Recent
|
Median YTD
|
|
$2,285
|
-37.13%
|
ECCU
|
$1,911
|
JFM WINTER
|
-39.16%
|
4.35%
|
GENEGURU
|
3.534%
|
|
